On the other hand, Thomas et al. [142] evaluated the association between ABCD-GENE (age, body mass index, chronic kidney disease, diabetes, and CYP2C19 genetic variants) score and the effectiveness of clopidogrel vs. alternative P2Y12 inhibitor (prasugrel or ticagrelor) therapy after PCI. This evidence concerns the gene CYP2C19 and chronic kidney disease.